Patient and GVHD characteristics
| . | Primary Tx cohort . | Second-line Tx cohort . | ||
|---|---|---|---|---|
| JSTCT . | MAGIC . | JSTCT . | MAGIC . | |
| n = 3497 . | n = 1141 . | n = 510 . | n = 196 . | |
| Median age at HCT (IQR), y | 53 (42-61) | 58 (45-65) | 55 (44-62) | 58 (42.75-64) |
| Age, category, n (%) | ||||
| <50 years | 1455 (41.6) | 473 (41.5) | 186 (36.5) | 83 (42.3) |
| ≥50 years | 2042 (58.4) | 668 (58.5) | 324 (63.5) | 113 (57.7) |
| Sex match between recipient and donor, n (%) | ||||
| Female to male | 728 (20.8) | 175 (15.4) | 85 (16.7) | 33 (16.9) |
| Other | 2769 (79.2) | 965 (84.6) | 425 (83.3) | 162 (83.1) |
| Race, n (%) | ||||
| Asian | 3486 (99.7) | 46 (4.0) | 508 (99.6) | 13 (6.6) |
| White | 2 (0.0) | 950 (83.3) | 0 (0.0) | 153 (78.1) |
| Black | 0 (0.0) | 52 (4.6) | 0 (0.0) | 9 (4.6) |
| Others | 9 (0.3) | 9 (0.8) | 2 (0.4) | 2 (1.0) |
| Unknown | 0 (0.0) | 84 (7.4) | 0 (0.0) | 19 (9.7) |
| Primary disease, n (%) | ||||
| Acute leukemia | 2137 (61.1) | 604 (52.9) | 281 (55.1) | 93 (47.4) |
| MDS/MPN | 720 (20.6) | 316 (27.7) | 128 (25.1) | 62 (31.6) |
| Malignant lymphoma | 523 (15.0) | 88 (7.7) | 85 (16.7) | 18 (9.2) |
| Other malignancies | 44 (1.3) | 94 (8.2) | 11 (2.2) | 17 (8.7) |
| Nonmalignancies | 73 (2.1) | 39 (3.4) | 5 (1.0) | 6 (3.1) |
| HCT-CI, n (%) | ||||
| <3 | 2912 (83.7) | 726 (63.6) | 429 (84.4) | 122 (62.2) |
| ≥3 | 566 (16.3) | 415 (36.4) | 79 (15.6) | 74 (37.8) |
| Donor source, n (%) | ||||
| HLA matched related | 590 (16.9) | 247 (21.6) | 70 (13.7) | 43 (21.9) |
| HLA mismatched related | 78 (2.2) | 8 (0.7) | 8 (1.6) | 1 (0.5) |
| HLA matched unrelated | 719 (20.6) | 618 (54.2) | 107 (21.0) | 113 (57.7) |
| HLA mismatched unrelated | 602 (17.2) | 99 (8.7) | 85 (16.7) | 21 (10.7) |
| Umbilical cord blood | 1175 (33.6) | 38 (3.3) | 182 (35.7) | 10 (5.1) |
| Haploidentical | 333 (9.5) | 131 (11.5) | 58 (11.4) | 8 (4.1) |
| Conditioning intensity, n (%) | ||||
| Myeloablative | 2251 (64.4) | 606 (53.1) | 315 (61.8) | 100 (51.0) |
| Reduced intensity | 1246 (35.6) | 535 (46.9) | 195 (38.2) | 96 (49.0) |
| Posttransplant cyclophosphamide, n (%) | ||||
| No | 3287 (94.0) | 934 (81.9) | 493 (96.7) | 178 (90.8) |
| Yes | 210 (6.0) | 207 (18.1) | 17 (3.3) | 18 (9.2) |
| In vivo T-cell depletion, n (%) | ||||
| No | 3055 (87.4) | 717 (62.8) | 427 (83.7) | 120 (61.2) |
| Yes | 442 (12.6) | 424 (37.2) | 83 (16.3) | 76 (38.8) |
| Median year of HCT (IQR) | 2018 (2016-2020) | 2018 (2016-2020) | 2018 (2016-2020) | 2018 (2016-2020) |
| GVHD grades at Tx onset, n (%) | ||||
| Grade 2 | 2545 (72.8) | 823 (72.1) | 135 (26.5) | 70 (35.7) |
| Grade 3 | 799 (22.8) | 257 (22.5) | 264 (51.8) | 73 (37.2) |
| Grade 4 | 153 (4.4) | 61 (5.3) | 111 (21.8) | 53 (27.0) |
| GVHD grades on day 28, n (%) | ||||
| Grade 0 | 1933 (55.3) | 677 (59.3) | 153 (30.0) | 51 (26.0) |
| Grade 1 | 472 (13.5) | 122 (10.7) | 45 (8.8) | 12 (6.1) |
| Grade 2 | 419 (12.0) | 72 (6.3) | 135 (26.5) | 22 (11.2) |
| Grade 3 | 157 (4.5) | 24 (2.1) | 109 (21.4) | 12 (6.1) |
| Grade 4 | 55 (1.6) | 16 (1.4) | 54 (10.6) | 9 (4.6) |
| Additional systemic Tx before day 28 | 461 (13.2) | 230 (20.2) | 14 (2.7) | 90 (45.9) |
| Days from HCT to treatment (IQR) | 34 (26-48) | 35 (23-61) | 50 (37-72) | 43 (35-59.5) |
| Median initial corticosteroid dose (methylprednisolone [mg/kg], IQR) | — | 1.0 (0.75-1.84) | NA | NA |
| Days from primary Tx to second-line Tx (IQR) | NA | NA | 12.5 (8-26) | 13 (7-23) |
| 6-Month NRM (95% CI), % | 16.7 (15.5-18.0) | 17.2 (15.0-19.5) | 44.0 (39.5-48.3) | 41.7 (34.6-48.6) |
| . | Primary Tx cohort . | Second-line Tx cohort . | ||
|---|---|---|---|---|
| JSTCT . | MAGIC . | JSTCT . | MAGIC . | |
| n = 3497 . | n = 1141 . | n = 510 . | n = 196 . | |
| Median age at HCT (IQR), y | 53 (42-61) | 58 (45-65) | 55 (44-62) | 58 (42.75-64) |
| Age, category, n (%) | ||||
| <50 years | 1455 (41.6) | 473 (41.5) | 186 (36.5) | 83 (42.3) |
| ≥50 years | 2042 (58.4) | 668 (58.5) | 324 (63.5) | 113 (57.7) |
| Sex match between recipient and donor, n (%) | ||||
| Female to male | 728 (20.8) | 175 (15.4) | 85 (16.7) | 33 (16.9) |
| Other | 2769 (79.2) | 965 (84.6) | 425 (83.3) | 162 (83.1) |
| Race, n (%) | ||||
| Asian | 3486 (99.7) | 46 (4.0) | 508 (99.6) | 13 (6.6) |
| White | 2 (0.0) | 950 (83.3) | 0 (0.0) | 153 (78.1) |
| Black | 0 (0.0) | 52 (4.6) | 0 (0.0) | 9 (4.6) |
| Others | 9 (0.3) | 9 (0.8) | 2 (0.4) | 2 (1.0) |
| Unknown | 0 (0.0) | 84 (7.4) | 0 (0.0) | 19 (9.7) |
| Primary disease, n (%) | ||||
| Acute leukemia | 2137 (61.1) | 604 (52.9) | 281 (55.1) | 93 (47.4) |
| MDS/MPN | 720 (20.6) | 316 (27.7) | 128 (25.1) | 62 (31.6) |
| Malignant lymphoma | 523 (15.0) | 88 (7.7) | 85 (16.7) | 18 (9.2) |
| Other malignancies | 44 (1.3) | 94 (8.2) | 11 (2.2) | 17 (8.7) |
| Nonmalignancies | 73 (2.1) | 39 (3.4) | 5 (1.0) | 6 (3.1) |
| HCT-CI, n (%) | ||||
| <3 | 2912 (83.7) | 726 (63.6) | 429 (84.4) | 122 (62.2) |
| ≥3 | 566 (16.3) | 415 (36.4) | 79 (15.6) | 74 (37.8) |
| Donor source, n (%) | ||||
| HLA matched related | 590 (16.9) | 247 (21.6) | 70 (13.7) | 43 (21.9) |
| HLA mismatched related | 78 (2.2) | 8 (0.7) | 8 (1.6) | 1 (0.5) |
| HLA matched unrelated | 719 (20.6) | 618 (54.2) | 107 (21.0) | 113 (57.7) |
| HLA mismatched unrelated | 602 (17.2) | 99 (8.7) | 85 (16.7) | 21 (10.7) |
| Umbilical cord blood | 1175 (33.6) | 38 (3.3) | 182 (35.7) | 10 (5.1) |
| Haploidentical | 333 (9.5) | 131 (11.5) | 58 (11.4) | 8 (4.1) |
| Conditioning intensity, n (%) | ||||
| Myeloablative | 2251 (64.4) | 606 (53.1) | 315 (61.8) | 100 (51.0) |
| Reduced intensity | 1246 (35.6) | 535 (46.9) | 195 (38.2) | 96 (49.0) |
| Posttransplant cyclophosphamide, n (%) | ||||
| No | 3287 (94.0) | 934 (81.9) | 493 (96.7) | 178 (90.8) |
| Yes | 210 (6.0) | 207 (18.1) | 17 (3.3) | 18 (9.2) |
| In vivo T-cell depletion, n (%) | ||||
| No | 3055 (87.4) | 717 (62.8) | 427 (83.7) | 120 (61.2) |
| Yes | 442 (12.6) | 424 (37.2) | 83 (16.3) | 76 (38.8) |
| Median year of HCT (IQR) | 2018 (2016-2020) | 2018 (2016-2020) | 2018 (2016-2020) | 2018 (2016-2020) |
| GVHD grades at Tx onset, n (%) | ||||
| Grade 2 | 2545 (72.8) | 823 (72.1) | 135 (26.5) | 70 (35.7) |
| Grade 3 | 799 (22.8) | 257 (22.5) | 264 (51.8) | 73 (37.2) |
| Grade 4 | 153 (4.4) | 61 (5.3) | 111 (21.8) | 53 (27.0) |
| GVHD grades on day 28, n (%) | ||||
| Grade 0 | 1933 (55.3) | 677 (59.3) | 153 (30.0) | 51 (26.0) |
| Grade 1 | 472 (13.5) | 122 (10.7) | 45 (8.8) | 12 (6.1) |
| Grade 2 | 419 (12.0) | 72 (6.3) | 135 (26.5) | 22 (11.2) |
| Grade 3 | 157 (4.5) | 24 (2.1) | 109 (21.4) | 12 (6.1) |
| Grade 4 | 55 (1.6) | 16 (1.4) | 54 (10.6) | 9 (4.6) |
| Additional systemic Tx before day 28 | 461 (13.2) | 230 (20.2) | 14 (2.7) | 90 (45.9) |
| Days from HCT to treatment (IQR) | 34 (26-48) | 35 (23-61) | 50 (37-72) | 43 (35-59.5) |
| Median initial corticosteroid dose (methylprednisolone [mg/kg], IQR) | — | 1.0 (0.75-1.84) | NA | NA |
| Days from primary Tx to second-line Tx (IQR) | NA | NA | 12.5 (8-26) | 13 (7-23) |
| 6-Month NRM (95% CI), % | 16.7 (15.5-18.0) | 17.2 (15.0-19.5) | 44.0 (39.5-48.3) | 41.7 (34.6-48.6) |
HCT-CI, HCT-specific comorbidity index; IQR, interquartile range; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; NA, not applicable; Tx, treatment.